Thomas J. Miner

Thomas J. Miner

Auto-generated profile, based on publicly available information

Thomas J. Miner

Department of Surgery, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, RI, USA

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2007 in Cancer Investigation
Verified
Journal Article
Closed access
DEDevon Evans
Devon Evans
TMThomas Miner
Thomas Miner
DIDavid Iannitti
David Iannitti
PAPaul Akerman
Paul Akerman
DCDennis Cruff
Dennis Cruff
HSHoward Safran
Howard Safran
A Phase I investigation of docetaxel, carboplatin, and capecitabine at our institution demonstrated the safety and tolerability of this regimen in patients with metastatic esophagogastric cancer. The objectives of this Phase II study were to determine the response rate, toxicity, and survival for patients with metastatic esophagogastric cancer treated with this regimen. Chemotherapy naïve patients with metastatic esophageal or gastric cancer received a regimen comprised of docetaxel 40 mg/m(2), days 1 and 8, carboplatin AUC = 2, Days 1 and 8, and capecitabine 2000 mg/m(2), Days 1-10 in 21-Day cycles. Patients were treated until disease progression or unacceptable toxicity. Twenty-five patients were treated with a median of 4 cycles of chemotherapy. Twelve of 25 patients (48 percent) had a Grade 3/4 toxicity. There were no Grade 4 nonhematologic toxicities, and 1 patient (4 percent) had neutropenic fever. There were 3 complete responses, and 9 partial responses, for an overall response rate of 48 percent. The median survival was 8 months (95% confidence interval, 5.5-13 months), and the 1-year survival was 36 percent. Weekly docetaxel and carboplatin with capecitabine was an easily administered outpatient regimen. The response rate and 1-year survival were similar to more complex regimens. Future trials may investigate the substitution of carboplatin with more active agents.

31 May 2021 in Annals of Hepato-Biliary-Pancreatic Surgery
Verified
Journal Article
Open access
PDF file
JCJoshua T. Cohen
Joshua T. Cohen
KCKevin P. Charpentier
Kevin P. Charpentier
TMThomas J. Miner
Thomas J. Miner
WCWilliam G. Cioffi
William G. Cioffi
RBRachel E. Beard
Rachel E. Beard
Joshua T. Cohen, Kevin P. Charpentier, Thomas J. Miner, William G. Cioffi, and Rachel E. Beard. Ann Hepatobiliary Pancreat Surg 2021;25:242-50. https://doi.org/10.14701/ahbps.2021.25.2.242

1 September 1998 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
TMThomas J. Miner
Thomas J. Miner
CSCraig Shriver
Craig Shriver
ACAudrey Chang
Audrey Chang